Update 2 : August 15, 2013 

The summit is free and open to the public
Online registration is open - click the summit logo above. 
 
**********
 
Featured Session Speakers 

 
***** 

 
   Visit PHEN       TV  
Like us on Facebook
           Like Us 
Follow us on Twitter
           Follow Us 
View our videos on YouTube
           View Our                 Videos 





Summit Session Highlight 
"Active Surveillance - To Treat or Not to Treat Prostate Cancer"

Friday, September 20th | 8:30 am - 12:00 pm 
Summit Venue: Biotechnology Industry Organization
1201 Maryland Ave., SW | Suite 900 | Washington, DC 20024

About the Session: 
Delaying the immediate treatment of prostate cancer through active surveillance has gained increased support from medical experts. This session will present the concept of active surveillance, the scientific evidence supporting it and the known benefits and risks for patients. The session will also examine how this treatment option may apply to African American patients. 
 
*****
Featured Session Speakers 
  
Professor of Urology, Oncology, Johns Hopkins Medicine 
Director, Division of Adult Urology,  Brady Urological Institute  
 

Dr. Carter runs the Active Surveillance program for prostate cancer at Johns Hopkins. He pioneered the concept of PSA rate of change (PSA velocity) as a marker of prostate cancer presence to predict the behavior of prostate cancer . He was the first to publish data demonstrating that an individual's personal prostate cancer screening program should be tailored to baseline PSA levels performed at an early age instead of using a "one size fits all" approach.

 

Edward M. Schaeffer, M.D., Ph.D.
Associate Professor of Urology, Oncology, Pathology 
Director International Urology
Co-Director Prostate Cancer Multi-Disciplinary Clinic 
Johns Hopkins Medical Institutions  

 

Dr. Schaeffer co-authored a study about active surveillance and its impact on African American men; Active Surveillance May Miss Agressive Prostate Cancers in Black Men. The study was published in the August 10, 2013 issue of the Journal of Clinical Oncology
 

 

***** 
Summit Sponsors